Asset Management One Co. Ltd. reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 107,119 shares of the medical equipment provider’s stock after selling 4,530 shares during the quarter. Asset Management One Co. Ltd. owned 0.05% of Zimmer Biomet worth $15,677,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Tradition Wealth Management LLC purchased a new stake in Zimmer Biomet in the 2nd quarter worth about $30,000. Tompkins Financial Corp bought a new position in Zimmer Biomet in the 3rd quarter valued at $36,000. Strategic Blueprint LLC bought a new position in Zimmer Biomet in the 2nd quarter valued at $48,000. Isthmus Partners LLC bought a new position in Zimmer Biomet in the 2nd quarter valued at $50,000. Finally, Covington Capital Management grew its position in Zimmer Biomet by 40.0% in the 2nd quarter. Covington Capital Management now owns 350 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 100 shares during the last quarter. 88.54% of the stock is currently owned by institutional investors.
In other news, insider Sang Yi sold 2,800 shares of Zimmer Biomet stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $124.14, for a total transaction of $347,592.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.56% of the company’s stock.
Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Zimmer Biomet from a “sell” rating to a “hold” rating and set a $152.00 price objective for the company in a research report on Friday, September 10th. Royal Bank of Canada initiated coverage on shares of Zimmer Biomet in a research report on Thursday, December 9th. They issued a “sector perform” rating and a $140.00 price objective for the company. Piper Sandler decreased their target price on Zimmer Biomet from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Thursday, November 4th. Deutsche Bank Aktiengesellschaft decreased their target price on Zimmer Biomet from $160.00 to $140.00 and set a “hold” rating for the company in a research report on Friday, November 5th. Finally, Jefferies Financial Group decreased their target price on Zimmer Biomet from $200.00 to $175.00 and set a “buy” rating for the company in a research report on Friday, November 5th. Five investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $174.48.
Shares of ZBH stock opened at $126.99 on Friday. The business’s fifty day simple moving average is $132.82 and its 200-day simple moving average is $145.75. The company has a market cap of $26.53 billion, a PE ratio of 32.65, a PEG ratio of 2.65 and a beta of 1.24. The company has a current ratio of 1.81, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. Zimmer Biomet Holdings, Inc. has a 12-month low of $116.60 and a 12-month high of $180.36.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, November 4th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.76 by $0.05. Zimmer Biomet had a return on equity of 12.67% and a net margin of 10.39%. The business had revenue of $1.92 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter in the previous year, the firm earned $1.81 earnings per share. The company’s revenue was down .3% on a year-over-year basis. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.39 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 31st. Stockholders of record on Tuesday, December 28th will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, December 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.76%. Zimmer Biomet’s payout ratio is 24.68%.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It operates through the following segments: Americas and Global Businesses, EMEA, and Asia Pacific. The Americas and Global Businesses segment consists of U.S. and includes other North, Central and South American markets for all product categories as well as the global results for the Dental products division.
Further Reading: Moving Average – How it Helps Investors in Stock Selection
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).
Want More Great Investing Ideas?